Subjects n | 68 | 63 | |
Age yrs | 45.94±12.6 | 48.67±12.3 | 0.21¶ |
Sex | | | 1.00+ |
Female | 46 (67.7) | 42 (66.7) | |
Male | 22 (32.4) | 21 (33.3) | |
Ethnic origin | | | 0.58+ |
White | 57 (83.8) | 52 (82.5) | |
Black or African American | 7 (10.3) | 7 (11.1) | |
Asian | 2 (2.9) | 0 | |
Other | 2 (2.9) | 4 (6.4) | |
Body mass index kg·m−2 | 30.7±7.4 | 30.1±5.8 | 0.57+ |
Inhaled corticosteroids | 68 (100.0) | 63 (100.0) | |
Oral corticosteroids | 10 (14.7) | 10 (15.9) | 1.00+ |
LABA | 61 (89.7) | 56 (88.9) | 1.00+ |
History of environmental allergy | 47 (69) | 47 (75) | 0.56+ |
Pulmonary status at baseline | | | |
Actual FEV1 L | 2.09±0.7 | 2.02±0.61 | 0.56¶ |
FEV1 % pred | 65.3±12.9 | 64.5±11.7 | 0.71¶ |
FEV1 reversibility % | 22.7±11.0 | 21.4±10.4 | 0.49¶ |
Morning PEF L·min−1 | 299.7±103.2 | 291.6±105.6 | 0.67¶ |
Methacholine PC20#mg·mL−1 | 0.6 (0.1–8) | 1.1 (0.1–16) | 0.31# |
ACQ-5 score | 2.9±0.9 | 2.8±0.9 | 0.47¶ |
Rescue medications puffs·day−1 | 2.9±3.4 | 2.6±2.8 | 0.62¶ |